Dosentrx Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
6
Active:0
Completed:1
Trial Phases
1 Phases
Not Applicable:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Not Applicable
5 (100.0%)Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform
Not Applicable
Recruiting
- Conditions
- Any Solid Oral Medication
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Dosentrx Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06344416
- Locations
- 🇺🇸
Allina, Minneapolis, Minnesota, United States
🇺🇸Texas Oncology, Austin, Texas, United States
🇺🇸Virginia Cancer Center, Richmond, Virginia, United States
Non-randomized Observational Study to Evaluate ReX® in the Management of Solid Oral Medication.
Recruiting
- Conditions
- Any Solid Oral Medication
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Dosentrx Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06335758
- Locations
- 🇺🇸
OHC, Cincinnati, Ohio, United States
Evaluation of the ReX-C System, in Patients Receiving CFTR Modulators for the Treatment of Cystic Fibrosis (CF).
Not Applicable
- Conditions
- Adherence, MedicationCystic Fibrosis
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Dosentrx Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT04215796
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Select One, Israel
🇮🇱Carmel Medical Center, Haifa, Israel
Evaluation of ReX-C® System for Medication Adherence in Oncology Patients Taking Oral Oncolytics
Not Applicable
Suspended
- Conditions
- Side EffectOncologyAdherence, Medication
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Dosentrx Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04091711
- Locations
- 🇮🇱
Oncology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Evaluation of ReX-C System in Measurement and Improvement of Patients' Adherence.
Not Applicable
Recruiting
- Conditions
- Thromboembolism
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Dosentrx Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT03424330
- Locations
- 🇮🇱
Carmel Medical Center, Haifa, Israel
- Prev
- 1
- 2
- Next
News
No news found